Mission Pharmacal's StoneTrack Diagnostic Monitoring Test is a metabolicevaluation that provides a method of "tracking" patient progressand compliance to treatment. The semi-comprehensive metabolic evaluationmeasures seven risk factors for stone formation.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.